Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

NCT03407976 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Funding source withdrew financial support prior to start of Phase II portion of study

Conditions

Advanced Malignancies
Urothelial Carcinoma
MSI-H or dMMR Solid Tumors
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG: Apatinib
DRUG: Pembrolizumab

Sponsor

University of Utah

Collaborators

[object Object]